Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
() -- (Updates to add the latest stock move in the headline and the first paragraph.) Fate Therapeutics (FATE) shares were up more than 7% in Thursday trading after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate designed to treat autoimmune